Hanwha Power Systems signs MOU with TC Energy to accelerate commercialization of sCO2 power generation

Hanwha Power Systems signs MOU with TC Energy to accelerate commercialization of sCO2 power generation

Hanwha has signed an MOU with TC Energy, one of North America's largest natural gas pipeline operators, to develop next-generation clean power solutions. Project aims to commercialize super-critical CO2 waste heat recovery technology in a pipeline...

Banpu NEXT and Durapower ready for mass production at Thailand battery assembly plant, leading country's commercial electric vehicle transition

Banpu NEXT and Durapower ready for mass production at Thailand battery assembly plant, leading country's commercial electric vehicle transition

BANGKOK, Nov. 21, 2024 /PRNewswire/ -- Banpu NEXT, a subsidiary of Banpu PCL and a leading Net Zero Solutions provider in Asia-Pacific, together with Durapower * , a global leader in performance lithium battery storage solutions for the electric...

LG ANNOUNCES ORGANIZATIONAL CHANGES TO PROPEL FUTURE VISION 2030

LG ANNOUNCES ORGANIZATIONAL CHANGES TO PROPEL FUTURE VISION 2030

Strategic Restructuring to Enhance Synergy and Drive Growth in Key Business Areas SEOUL, South Korea, Nov. 21, 2024 /PRNewswire/ -- LG Electronics (LG) today announced a series of organizational changes and executive appointments following the...

DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation

DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation

This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a...

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRII A ) Antagonistic Monoclonal Antibody (mAb) for muscle-preserving weight loss in Obesity LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna,...

menu
menu